MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Xenon Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

39.3 0.41

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

38.22

Max

39.94

Schlüsselkennzahlen

By Trading Economics

Einkommen

-20M

-85M

Gewinnspanne

-867.293

Angestellte

316

EBITDA

-21M

-94M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+40.78% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

11. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

432M

3B

Vorheriger Eröffnungskurs

38.89

Vorheriger Schlusskurs

39.3

Nachrichtenstimmung

By Acuity

32%

68%

115 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Xenon Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Okt. 2025, 16:58 UTC

Ergebnisse

BMW Trims 2025 View, Citing Weaker Performance in China

7. Okt. 2025, 23:43 UTC

Market Talk

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7. Okt. 2025, 23:36 UTC

Market Talk

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7. Okt. 2025, 23:19 UTC

Market Talk

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7. Okt. 2025, 22:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Okt. 2025, 22:50 UTC

Market Talk

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7. Okt. 2025, 22:40 UTC

Market Talk

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7. Okt. 2025, 21:56 UTC

Market Talk

Global Equities Roundup: Market Talk

7. Okt. 2025, 21:56 UTC

Market Talk

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. Okt. 2025, 20:44 UTC

Heiße Aktien

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7. Okt. 2025, 19:42 UTC

Market Talk

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7. Okt. 2025, 19:23 UTC

Akquisitionen, Fusionen, Übernahmen

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7. Okt. 2025, 19:07 UTC

Market Talk

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7. Okt. 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7. Okt. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7. Okt. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. Okt. 2025, 16:20 UTC

Market Talk

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7. Okt. 2025, 16:15 UTC

Market Talk

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7. Okt. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. Okt. 2025, 15:37 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Okt. 2025, 15:37 UTC

Market Talk

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7. Okt. 2025, 15:33 UTC

Market Talk

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7. Okt. 2025, 15:25 UTC

Market Talk

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7. Okt. 2025, 15:15 UTC

Market Talk

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7. Okt. 2025, 15:04 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7. Okt. 2025, 15:04 UTC

Market Talk

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7. Okt. 2025, 14:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Okt. 2025, 14:56 UTC

Market Talk

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7. Okt. 2025, 14:52 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Peer-Vergleich

Kursveränderung

Xenon Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

40.78% Vorteil

12-Monats-Prognose

Durchschnitt 55.13 USD  40.78%

Hoch 65 USD

Tief 48 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Xenon Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

14 ratings

14

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

34.81 / 38.24Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Neutral Evidence

Stimmung

By Acuity

115 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
help-icon Live chat